BD announced the launch of its HemoSphere Stream™ Module on April 7 2026. The new module delivers continuous, beat‑to‑beat arterial waveform data from a non‑invasive finger cuff directly to compatible multiparameter patient monitors, filling a gap for patients who do not require invasive arterial lines.
The HemoSphere Stream™ Module mounts on an IV pole and works with the VitaWave™ Plus Finger Cuff to provide real‑time, non‑invasive blood‑pressure monitoring. By enabling continuous hemodynamic insight, the system helps clinicians detect and treat intra‑operative hypotension sooner, aligning with the Anesthesia Patient Safety Foundation’s recommendations for continuous monitoring.
The launch expands BD’s Advanced Patient Monitoring portfolio and strengthens its position in the critical‑care monitoring segment, which grew 5.5% in revenue in Q1 fiscal 2026. BD’s Connected Care segment, which includes Advanced Patient Monitoring, reported a 5.5% revenue increase in Q1, reflecting strong demand for connected monitoring solutions.
BD’s Q1 fiscal 2026 results, announced February 9 2026, showed revenue of $5.3 billion, a 1.6% year‑over‑year increase, and adjusted diluted EPS of $2.91. The company highlighted disciplined execution and accelerated commercial initiatives as drivers of the growth, positioning the new module as part of its broader strategy to deliver connected, data‑driven care solutions.
Tim Patz, worldwide president of Advanced Patient Monitoring, said the HemoSphere Stream Module “delivers real‑time visibility of hemodynamic changes to more patients and care settings by making continuous, non‑invasive monitoring available on compatible multiparameter monitors.” The technology uses the Volume Clamp and Physiocal methods, validated against arterial line measurements, offering accuracy comparable to invasive methods.
The global critical‑care devices market was valued at approximately $60.1 billion in 2024 and is projected to grow at a 5.5% CAGR through 2034. By providing continuous, non‑invasive blood‑pressure monitoring, BD taps into a growing market that demands safer, more efficient patient monitoring, positioning the company to capture additional market share following its acquisition of Edwards Lifesciences’ critical‑care product group in September 2024.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.